Cantuzumab mertansine
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | MUC1 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
(what is this?) (verify) |
Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate used to treat colorectal cancer and other types of cancer.[1] It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1).[2]
Mechanism
After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.[3]
Clinical trials
Three phase I clinical studies had reported results by 2003.[4]
See also
References
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Cantuzumab mertansine, American Medical Association.[dead link]
- ^ Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Rodon et al. 2008
- ^ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004
- ^ http://phx.corporate-ir.net/phoenix.zhtml?c=97573&p=irol-newsArticle&ID=354351&highlight=